Abstract:Patients in their first psychotic episode often respond to antipsychotic medications, with rates of response up to 80%. The OPTIMISE project was a large three-phase multicenter study, which included 446 patients in their first psychotic episode, who received open-label amisulpride, and/or double-blind amisulpride or olanzapine for 10 weeks. Of the patients recruited, 63% went into remission, as defined by the Andreasen criteria. This present study attempted to identify predictors of later relapse in these initial remitters during a follow-up period of up to a year and a half. Relapse was defined by changes of PANSS scores compared to time of remission at any time during the follow-up period using one of two different criteria: (1) ≥ 20% increase in total PANSS score from the time of remission, or (2) no longer meeting one or more of the Andreasen criteria. Potential predictors tested in the analyses were age, sex, duration of untreated psychosis, cannabis use, baseline PANSS scores, and insight, as measured by the drug attitude inventory (DAI) scale and the Knowledge of Psychotic Illness (KPI) Questionnaire. Univariate analyses examining the effect of each of these potential predictors on risk for relapse were performed. Those variables who were significant in the univariate analyses were included in a multivariate logistic regression. When using the 20% increase of PANSS criterion for relapse, a total of 67 out of 446 patients (15%) were included in the analyses, using the criterion of no longer meeting Andreasen criteria identified 101 out of 446 (23%) patients. When using the relapse criterion of 20% increase in PANSS, univariate analyses showed a significant effect on relapse, with lower baseline score increasing risk of relapse: for baseline positive PANSS score (OR=0.918, 95% CI: 0.868–0.971, p=0.003), baseline negative PANSS score (OR=0.926, 95% CI: 0.883–0.972, p=0.002), baseline general psychopathology PANSS score (OR=0.943, 95% CI: 0.911–0.976, p=0.001), and cannabis use (OR=2.284, 95% CI: 1.116–4.678, p=0.024). Multivariate analyses showed significant effects on relapse only for cannabis use (OR=2.011, 95% CI:1.024–4.087, p=0.021). Both univariate and multivariate analyses were not significant when using the relapse criterion of not meeting one or more Andreasen criteria. Cannabis use was the only significant clinical factor that increased risk for relapse. These findings are similar to previous studies which showed a strong correlation between cannabis use and earlier and more frequent relapses. Patients and family members should be made aware of this finding and future studies should investigate the effect of cannabis cessation programs on relapse rates.

The Role of Depression in the Prediction of a “late” Remission in First-Episode Psychosis: an Analysis of the OPTiMiSE Study

Stratification and prediction of remission in first-episode psychosis patients OPTIMISE

Predictive Value of Prospective Memory for Remission in First-Episode Schizophrenia.

Duration of Untreated Psychosis and Response to Treatment: an Analysis of Response in the OPTiMiSE Cohort

Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: the OPTiMiSE Study.

Stratification and Prediction of Remission in First-Episode Psychosis Patients: the OPTiMiSE Cohort Study

Employment, education or training status (NEET) at baseline predicts high‐threshold symptomatic remission in first episode psychosis: A cohort study

Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?

Baseline Levels of C-reactive Protein and Proinflammatory Cytokines Are Not Associated with Early Response to Amisulpride in Patients with First Episode Psychosis: the OPTiMiSE Cohort Study

17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION

T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA

Anxious-depressive symptoms after a first episode of schizophrenia: Response to treatment and psychopathological considerations from a 2-year follow-up study in Italy

Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis

Insight and Suicidality in First Episode Psychosis: The Mediating Role of Depression

Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses

Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia

Clinical, psychological and brain imaging investigation of first episode psychosis patients treated at Semmelweis University, Department of Psychiatry and Psychotherapy, Budapest, Hungary

Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study

Predictors of Response to Second Generation Antipsychotics in Drug Naïve Patients with Schizophrenia: A 1 Year Follow-Up Study in Shanghai

Association of Complement and Coagulation Pathway Proteins with Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial

Achieving functional remission in schizophrenia: a pilot study